Published in

Public Library of Science, PLoS Medicine, 7(11), p. e1001675, 2014

DOI: 10.1371/journal.pmed.1001675

Links

Tools

Export citation

Search in Google Scholar

Defining Catastrophic Costs and Comparing Their Importance for Adverse Tuberculosis Outcome with Multi-Drug Resistance: A Prospective Cohort Study, Peru

Journal article published in 2014 by Tom Wingfield ORCID, Delia Boccia, K. L??nnroth, Asociaci??n Ben??fica PRISMA Lima Per??; Innovation For Health And Development (IFHAD) London United Kingdom; Infectious Diseases & Immunity Imperial College London and Wellcome Trust Imperial College Centre for Global Health Research London United Kin Innovaci??n Por la Salud Y. Desarrollo (IPSYD), Marco Tovar, Arquímedes Gavino, London United Kingdom; Department of Infectious Disease Epidemiology London School of Hygiene & Tropical Medicine London United Kingdom Innovation For Health And Development (IFHAD), Asociaci??n Ben??fica PRISMA Lima Per??; Innovation For Health And Development (IFHAD) London United Kingdom Innovaci??n Por la Salud Y. Desarrollo (IPSYD), Karine Zevallos, London United Kingdom Innovation For Health And Development (IFHAD), Rosario Montoya, Asociaci??n Ben??fica PRISMA Lima Per??; Innovation For Health And Development (IFHAD) London United Kingdom; Laboratorio de Investigaci??n y. Desarrollo Universidad Peruana Cayetano Heredia Lima Per?? Innovaci??n Por la Salud Y. Desarrollo (IPSYD), Knut Lönnroth, Stop Tb Department World Health Organization Geneva Switzerland Policy Strategy and Innovations, Carlton A. Evans and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Journal Article; Research Support, Non-U.S. Gov't ; BACKGROUND: Even when tuberculosis (TB) treatment is free, hidden costs incurred by patients and their households (TB-affected households) may worsen poverty and health. Extreme TB-associated costs have been termed "catastrophic" but are poorly defined. We studied TB-affected households' hidden costs and their association with adverse TB outcome to create a clinically relevant definition of catastrophic costs. METHODS AND FINDINGS: From 26 October 2002 to 30 November 2009, TB patients (n???=???876, 11% with multi-drug-resistant [MDR] TB) and healthy controls (n???=???487) were recruited to a prospective cohort study in shantytowns in Lima, Peru. Patients were interviewed prior to and every 2-4 wk throughout treatment, recording direct (household expenses) and indirect (lost income) TB-related costs. Costs were expressed as a proportion of the household's annual income. In poorer households, costs were lower but constituted a higher proportion of the household's annual income: 27% (95% CI???=???20%-43%) in the least-poor houses versus 48% (95% CI???=???36%-50%) in the poorest. Adverse TB outcome was defined as death, treatment abandonment or treatment failure during therapy, or recurrence within 2 y. 23% (166/725) of patients with a defined treatment outcome had an adverse outcome. Total costs ???20% of household annual income was defined as catastrophic because this threshold was most strongly associated with adverse TB outcome. Catastrophic costs were incurred by 345 households (39%). Having MDR TB was associated with a higher likelihood of incurring catastrophic costs (54% [95% CI???=???43%-61%] versus 38% [95% CI???=???34%-41%], p